ASND:NSD-Ascendis Pharma A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 154.86

Change

-1.59 (-1.02)%

Market Cap

USD 8.41B

Volume

0.14M

Average Target Price

USD 190.11 (+22.76%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.94 (+0.82%)

USD61.55B 23.20 18.26
REGN Regeneron Pharmaceuticals, Inc

-6.79 (-1.25%)

USD57.86B 19.87 14.64
MRNA Moderna, Inc

+7.84 (+6.26%)

USD49.52B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+0.12 (+0.08%)

USD34.50B 36.61 33.83
SGEN Seagen Inc

-5.02 (-2.63%)

USD34.15B 72.05 70.76
BGNE BeiGene, Ltd

-5.81 (-1.60%)

USD33.65B N/A N/A
RPRX Royalty Pharma plc

+0.07 (+0.14%)

USD31.48B 22.60 11.90
GMAB Genmab A/S

-0.19 (-0.44%)

USD28.72B 26.59 3.08
BNTX BioNTech SE

+2.20 (+2.13%)

USD25.21B -99,999.99 N/A
INCY Incyte Corporation

-2.47 (-2.56%)

USD21.10B 47.64 35.20

ETFs Containing ASND

Symbol Name Weight Mer Price(Change) Market Cap
MEU:CA Mackenzie Maximum Diversi.. 0.00 % 0.61 %

N/A

USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.15% 9% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.15% 9% F 6% F
Trailing 12 Months  
Capital Gain 13.04% 48% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.04% 48% F 53% F
Trailing 5 Years  
Capital Gain 748.55% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 748.55% 94% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 74.74% 87% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.74% 87% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 42.18% 62% D- 31% F
Risk Adjusted Return 177.21% 100% A+ 99% A+
Market Capitalization 8.41B 94% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 97% A+
Price/Book Ratio 7.34 34% F 23% F
Price / Cash Flow Ratio -47.80 88% B+ 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -44.69% 66% D 24% F
Return on Invested Capital -51.64% 59% F 18% F
Return on Assets -21.04% 64% D 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 13.12 7% F 4% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.77 81% B- 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector